The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH
August 29th 2025Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.
Read More